Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2009

Open Access 01-12-2009 | Review

Protein kinase Cε: an oncogene and emerging tumor biomarker

Authors: Michael A Gorin, Quintin Pan

Published in: Molecular Cancer | Issue 1/2009

Login to get access

Abstract

Members of the protein kinase C (PKC) family have long been studied for their contributions to oncogenesis. Among the ten different isoforms of this family of serine/threonine kinases, protein kinase Cε (PKCε) is one of the best understood for its role as a transforming oncogene. In vitro, overexpression of PKCε has been demonstrated to increase proliferation, motility, and invasion of fibroblasts or immortalized epithelial cells. In addition, xenograft and transgenic animal models have clearly shown that overexpression of PKCε is tumorigenic resulting in metastatic disease. Perhaps most important in implicating the epsilon isoform in oncogenesis, PKCε has been found to be overexpressed in tumor-derived cell lines and histopathological tumor specimens from various organ sites. Combined, this body of work provides substantial evidence implicating PKCε as a transforming oncogene that plays a crucial role in establishing an aggressive metastatic phenotype. Reviewed here is the literature that has led to the current understanding of PKCε as an oncogene. Moreover, this review focuses on the PKCε-mediated signaling network for cell motility and explores the interaction of PKCε with three major PKCε signaling nodes: RhoA/C, Stat3 and Akt. Lastly, the emerging role of PKCε as a tumor biomarker is discussed.
Appendix
Available only for authorised users
Literature
1.
Jaken S: Protein kinase C isozymes and substrates. Curr Opin Cell Biol. 1996, 8 (2): 168-173. 10.1016/S0955-0674(96)80062-7PubMed
2.
Dempsey EC, Newton AC, Mochly-Rosen D, Fields AP, Reyland ME, Insel PA, Messing RO: Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol. 2000, 279 (3): L429-38.PubMed
3.
Gutcher I, Webb PR, Anderson NG: The isoform-specific regulation of apoptosis by protein kinase C. Cell Mol Life Sci. 2003, 60 (6): 1061-1070.PubMed
4.
Griner EM, Kazanietz MG: Protein kinase C and other diacylglycerol effectors in cancer. Nat Rev Cancer. 2007, 7 (4): 281-294. 10.1038/nrc2110PubMed
5.
Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y: Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. J Biol Chem. 1982, 257 (13): 7847-7851.PubMed
6.
Kikkawa U, Takai Y, Tanaka Y, Miyake R, Nishizuka Y: Protein kinase C as a possible receptor protein of tumor-promoting phorbol esters. J Biol Chem. 1983, 258 (19): 11442-11445.PubMed
7.
Leach KL, James ML, Blumberg PM: Characterization of a specific phorbol ester aporeceptor in mouse brain cytosol. Proc Natl Acad Sci USA. 1983, 80 (14): 4208-4212. 10.1073/pnas.80.14.4208PubMedCentralPubMed
8.
Jansen AP, Dreckschmidt NE, Verwiebe EG, Wheeler DL, Oberley TD, Verma AK: Relation of the induction of epidermal ornithine decarboxylase and hyperplasia to the different skin tumor-promotion susceptibilities of protein kinase C alpha, -delta and -epsilon transgenic mice. Int J Cancer. 2001, 93 (5): 635-643. 10.1002/ijc.1395PubMed
9.
Reddig PJ, Dreckschmidt NE, Ahrens H, Simsiman R, Tseng CP, Zou J, Oberley TD, Verma AK: Transgenic mice overexpressing protein kinase Cdelta in the epidermis are resistant to skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 1999, 59 (22): 5710-5718.PubMed
10.
Jansen AP, Verwiebe EG, Dreckschmidt NE, Wheeler DL, Oberley TD, Verma AK: Protein kinase C-epsilon transgenic mice: a unique model for metastatic squamous cell carcinoma. Cancer Res. 2001, 61 (3): 808-812.PubMed
11.
Cameron AJ, Procyk KJ, Leitges M, Parker PJ: PKC alpha protein but not kinase activity is critical for glioma cell proliferation and survival. Int J Cancer. 2008, 123 (4): 769-779. 10.1002/ijc.23560PubMed
12.
Cohen EE, Zhu H, Lingen MW, Martin LE, Kuo WL, Choi EA, Kocherginsky M, Parker JS, Chung CH, Rosner MR: A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res. 2009, 69 (1): 65-74. 10.1158/0008-5472.CAN-08-0377PubMedCentralPubMed
13.
Baldwin RM, Parolin DA, Lorimer IA: Regulation of glioblastoma cell invasion by PKC iota and RhoB. Oncogene. 2008, 27 (25): 3587-3595. 10.1038/sj.onc.1211027PubMed
14.
Patel R, Win H, Desai S, Patel K, Matthews JA, Acevedo-Duncan M: Involvement of PKC-iota in glioma proliferation. Cell Prolif. 2008, 41 (1): 122-135.PubMed
15.
Perletti GP, Marras E, Concari P, Piccinini F, Tashjian AH: PKCdelta acts as a growth and tumor suppressor in rat colonic epithelial cells. Oncogene. 1999, 18 (5): 1251-1256. 10.1038/sj.onc.1202408PubMed
16.
Clark AS, West KA, Blumberg PM, Dennis PA: Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res. 2003, 63 (4): 780-786.PubMed
17.
McCracken MA, Miraglia LJ, McKay RA, Strobl JS: Protein kinase C delta is a prosurvival factor in human breast tumor cell lines. Mol Cancer Ther. 2003, 2 (3): 273-281.PubMed
18.
Mischak H, Goodnight JA, Kolch W, Martiny-Baron G, Schaechtle C, Kazanietz MG, Blumberg PM, Pierce JH, Mushinski JF: Overexpression of protein kinase C-delta and -epsilon in NIH 3T3 cells induces opposite effects on growth, morphology, anchorage dependence, and tumorigenicity. J Biol Chem. 1993, 268 (9): 6090-6096.PubMed
19.
Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB: The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene. 1993, 8 (8): 2095-2104.PubMed
20.
Perletti GP, Folini M, Lin HC, Mischak H, Piccinini F, Tashjian AH: Overexpression of protein kinase C epsilon is oncogenic in rat colonic epithelial cells. Oncogene. 1996, 12 (4): 847-854.PubMed
21.
Cacace AM, Ueffing M, Philipp A, Han EK, Kolch W, Weinstein IB: PKC epsilon functions as an oncogene by enhancing activation of the Raf kinase. Oncogene. 1996, 13 (12): 2517-2526.PubMed
22.
Cai H, Smola U, Wixler V, Eisenmann-Tappe I, Diaz-Meco MT, Moscat J, Rapp U, Cooper GM: Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol. 1997, 17 (2): 732-741.PubMedCentralPubMed
23.
Ueffing M, Lovric J, Philipp A, Mischak H, Kolch W: Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity. Oncogene. 1997, 15 (24): 2921-2927. 10.1038/sj.onc.1201477PubMed
24.
Perletti GP, Concari P, Brusaferri S, Marras E, Piccinini F, Tashjian AH: Protein kinase Cepsilon is oncogenic in colon epithelial cells by interaction with the ras signal transduction pathway. Oncogene. 1998, 16 (25): 3345-3348. 10.1038/sj.onc.1201871PubMed
25.
Malumbres M, Barbacid M: RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003, 3 (6): 459-465. 10.1038/nrc1097PubMed
26.
Albanese C, Johnson J, Watanabe G, Eklund N, Vu D, Arnold A, Pestell RG: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem. 1995, 270 (40): 23589-23597. 10.1074/jbc.270.40.23589PubMed
27.
Lavoie JN, Rivard N, L'Allemain G, Pouyssegur J: A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. Prog Cell Cycle Res. 1996, 2: 49-58.PubMed
28.
Weber JD, Hu W, Jefcoat SC, Raben DM, Baldassare JJ: Ras-stimulated extracellular signal-related kinase 1 and RhoA activities coordinate platelet-derived growth factor-induced G1 progression through the independent regulation of cyclin D1 and p27. J Biol Chem. 1997, 272 (52): 32966-32971. 10.1074/jbc.272.52.32966PubMed
29.
Cheng M, Sexl V, Sherr CJ, Roussel MF: Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1). Proc Natl Acad Sci USA. 1998, 95 (3): 1091-1096. 10.1073/pnas.95.3.1091PubMedCentralPubMed
30.
Kampfer S, Windegger M, Hochholdinger F, Schwaiger W, Pestell RG, Baier G, Grunicke HH, Uberall F: Protein kinase C isoforms involved in the transcriptional activation of cyclin D1 by transforming Ha-Ras. J Biol Chem. 2001, 276 (46): 42834-42842. 10.1074/jbc.M102047200PubMed
31.
Soh JW, Weinstein IB: Roles of specific isoforms of protein kinase C in the transcriptional control of cyclin D1 and related genes. J Biol Chem. 2003, 278 (36): 34709-34716. 10.1074/jbc.M302016200PubMed
32.
Ding L, Wang H, Lang W, Xiao L: Protein kinase C-epsilon promotes survival of lung cancer cells by suppressing apoptosis through dysregulation of the mitochondrial caspase pathway. J Biol Chem. 2002, 277 (38): 35305-35313. 10.1074/jbc.M201460200PubMed
33.
Pardo OE, Arcaro A, Salerno G, Raguz S, Downward J, Seckl MJ: Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis. J Biol Chem. 2002, 277 (14): 12040-12046. 10.1074/jbc.M109006200PubMed
34.
McJilton MA, Van Sikes C, Wescott GG, Wu D, Foreman TL, Gregory CW, Weidner DA, Harris Ford O, Morgan Lasater A, Mohler JL, Terrian DM: Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene. 2003, 22 (39): 7958-7968. 10.1038/sj.onc.1206795PubMed
35.
Pardo OE, Lesay A, Arcaro A, Lopes R, Ng BL, Warne PH, McNeish IA, Tetley TD, Lemoine NR, Mehmet H, Seckl MJ, Downward J: Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells. Mol Cell Biol. 2003, 23 (21): 7600-7610. 10.1128/MCB.23.21.7600-7610.2003PubMedCentralPubMed
36.
Pardo OE, Wellbrock C, Khanzada UK, Aubert M, Arozarena I, Davidson S, Bowen F, Parker PJ, Filonenko VV, Gout IT, Sebire N, Marais R, Downward J, Seckl MJ: FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J. 2006, 25 (13): 3078-3088. 10.1038/sj.emboj.7601198PubMedCentralPubMed
37.
Lu D, Sivaprasad U, Huang J, Shankar E, Morrow S, Basu A: Protein kinase C-epsilon protects MCF-7 cells from TNF-mediated cell death by inhibiting Bax translocation. Apoptosis. 2007, 12 (10): 1893-1900. 10.1007/s10495-007-0111-7PubMed
38.
Sivaprasad U, Shankar E, Basu A: Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance. Cell Death Differ. 2007, 14 (4): 851-860. 10.1038/sj.cdd.4402077PubMed
39.
Wu D, Thakore CU, Wescott GG, McCubrey JA, Terrian DM: Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene. 2004, 23 (53): 8659-8672. 10.1038/sj.onc.1207900PubMed
40.
Okhrimenko H, Lu W, Xiang C, Hamburger N, Kazimirsky G, Brodie C: Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res. 2005, 65 (16): 7301-7309. 10.1158/0008-5472.CAN-05-1064PubMedCentralPubMed
41.
Lu D, Huang J, Basu A: Protein kinase Cepsilon activates protein kinase B/Akt via DNA-PK to protect against tumor necrosis factor-alpha-induced cell death. J Biol Chem. 2006, 281 (32): 22799-22807. 10.1074/jbc.M603390200PubMed
42.
Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002, 2 (7): 489-501. 10.1038/nrc839PubMed
43.
Basu A, Sivaprasad U: Protein kinase Cepsilon makes the life and death decision. Cell Signal. 2007, 19 (8): 1633-1642. 10.1016/j.cellsig.2007.04.008PubMedCentralPubMed
44.
Tachado SD, Mayhew MW, Wescott GG, Foreman TL, Goodwin CD, McJilton MA, Terrian DM: Regulation of tumor invasion and metastasis in protein kinase C epsilon-transformed NIH3T3 fibroblasts. J Cell Biochem. 2002, 85 (4): 785-797. 10.1002/jcb.10164PubMed
45.
Pan Q, Bao LW, Kleer CG, Sabel MS, Griffith KA, Teknos TN, Merajver SD: Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res. 2005, 65 (18): 8366-8371. 10.1158/0008-5472.CAN-05-0553PubMed
46.
Pan Q, Bao LW, Teknos TN, Merajver SD: Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res. 2006, 66 (19): 9379-9384. 10.1158/0008-5472.CAN-06-2646PubMedCentralPubMed
47.
Prekeris R, Hernandez RM, Mayhew MW, White MK, Terrian DM: Molecular analysis of the interactions between protein kinase C-epsilon and filamentous actin. J Biol Chem. 1998, 273 (41): 26790-26798. 10.1074/jbc.273.41.26790PubMed
48.
Hernandez RM, Wescott GG, Mayhew MW, McJilton MA, Terrian DM: Biochemical and morphogenic effects of the interaction between protein kinase C-epsilon and actin in vitro and in cultured NIH3T3 cells. J Cell Biochem. 2001, 83 (4): 532-546. 10.1002/jcb.1246PubMed
49.
Chun JS, Ha MJ, Jacobson BS: Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum. J Biol Chem. 1996, 271 (22): 13008-13012. 10.1074/jbc.271.22.13008PubMed
50.
Berrier AL, Mastrangelo AM, Downward J, Ginsberg M, LaFlamme SE: Activated R-ras, Rac1, PI 3-kinase and PKCepsilon can each restore cell spreading inhibited by isolated integrin beta1 cytoplasmic domains. J Cell Biol. 2000, 151 (7): 1549-1560. 10.1083/jcb.151.7.1549PubMedCentralPubMed
51.
Ivaska J, Whelan RD, Watson R, Parker PJ: PKC epsilon controls the traffic of beta1 integrins in motile cells. EMBO J. 2002, 21 (14): 3608-3619. 10.1093/emboj/cdf371PubMedCentralPubMed
52.
Ivaska J, Vuoriluoto K, Huovinen T, Izawa I, Inagaki M, Parker PJ: PKCepsilon-mediated phosphorylation of vimentin controls integrin recycling and motility. EMBO J. 2005, 24 (22): 3834-3845. 10.1038/sj.emboj.7600847PubMedCentralPubMed
53.
Besson A, Davy A, Robbins SM, Yong VW: Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene. 2001, 20 (50): 7398-7407. 10.1038/sj.onc.1204899PubMed
54.
Besson A, Wilson TL, Yong VW: The anchoring protein RACK1 links protein kinase Cepsilon to integrin beta chains. Requirements for adhesion and motility. J Biol Chem. 2002, 277 (24): 22073-22084. 10.1074/jbc.M111644200PubMed
55.
Zhang J, Baines CP, Zong C, Cardwell EM, Wang G, Vondriska TM, Ping P: Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection. Am J Physiol Heart Circ Physiol. 2005, 288 (2): H954-61. 10.1152/ajpheart.00756.2004PubMed
56.
Zhou GL, Zhuo Y, King CC, Fryer BH, Bokoch GM, Field J: Akt phosphorylation of serine 21 on Pak1 modulates Nck binding and cell migration. Mol Cell Biol. 2003, 23 (22): 8058-8069. 10.1128/MCB.23.22.8058-8069.2003PubMedCentralPubMed
57.
Menard RE, Mattingly RR: Gbetagamma subunits stimulate p21-activated kinase 1 (PAK1) through activation of PI3-kinase and Akt but act independently of Rac1/Cdc42. FEBS Lett. 2004, 556 (1–3): 187-192. 10.1016/S0014-5793(03)01406-6PubMed
58.
Alberts AS, Qin H, Carr HS, Frost JA: PAK1 negatively regulates the activity of the Rho exchange factor NET1. J Biol Chem. 2005, 280 (13): 12152-12161. 10.1074/jbc.M405073200PubMed
59.
Sanders LC, Matsumura F, Bokoch GM, de Lanerolle P: Inhibition of myosin light chain kinase by p21-activated kinase. Science. 1999, 283 (5410): 2083-2085. 10.1126/science.283.5410.2083PubMed
60.
Ikebe M, Hartshorne DJ: Phosphorylation of smooth muscle myosin at two distinct sites by myosin light chain kinase. J Biol Chem. 1985, 260 (18): 10027-10031.PubMed
61.
Totsukawa G, Yamakita Y, Yamashiro S, Hartshorne DJ, Sasaki Y, Matsumura F: Distinct roles of ROCK (Rho-kinase) and MLCK in spatial regulation of MLC phosphorylation for assembly of stress fibers and focal adhesions in 3T3 fibroblasts. J Cell Biol. 2000, 150 (4): 797-806. 10.1083/jcb.150.4.797PubMedCentralPubMed
62.
Edwards DC, Sanders LC, Bokoch GM, Gill GN: Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nat Cell Biol. 1999, 1 (5): 253-259. 10.1038/12963PubMed
63.
Sumi T, Matsumoto K, Nakamura T: Specific activation of LIM kinase 2 via phosphorylation of threonine 505 by ROCK, a Rho-dependent protein kinase. J Biol Chem. 2001, 276 (1): 670-676. 10.1074/jbc.M007074200PubMed
64.
Maekawa M, Ishizaki T, Boku S, Watanabe N, Fujita A, Iwamatsu A, Obinata T, Ohashi K, Mizuno K, Narumiya S: Signaling from Rho to the actin cytoskeleton through protein kinases ROCK and LIM-kinase. Science. 1999, 285 (5429): 895-898. 10.1126/science.285.5429.895PubMed
65.
Amano T, Tanabe K, Eto T, Narumiya S, Mizuno K: LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505. Biochem J. 2001, 354 (Pt 1): 149-159. 10.1042/0264-6021:3540149PubMedCentralPubMed
66.
Aziz MH, Manoharan HT, Sand JM, Verma AK: Protein kinase Cepsilon interacts with Stat3 and regulates its activation that is essential for the development of skin cancer. Mol Carcinog. 2007, 46 (8): 646-653. 10.1002/mc.20356PubMed
67.
Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, Wilding G, Verma AK: Protein kinase Cepsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res. 2007, 67 (18): 8828-8838. 10.1158/0008-5472.CAN-07-1604PubMed
68.
Aziz MH, Manoharan HT, Verma AK: Protein kinase C epsilon, which sensitizes skin to sun's UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res. 2007, 67 (3): 1385-1394. 10.1158/0008-5472.CAN-06-3350PubMed
69.
Debidda M, Wang L, Zang H, Poli V, Zheng Y: A role of STAT3 in Rho GTPase-regulated cell migration and proliferation. J Biol Chem. 2005, 280 (17): 17275-17285. 10.1074/jbc.M413187200PubMed
70.
Ng DC, Lin BH, Lim CP, Huang G, Zhang T, Poli V, Cao X: Stat3 regulates microtubules by antagonizing the depolymerization activity of stathmin. J Cell Biol. 2006, 172 (2): 245-257. 10.1083/jcb.200503021PubMedCentralPubMed
71.
Beretta L, Dobransky T, Sobel A: Multiple phosphorylation of stathmin. Identification of four sites phosphorylated in intact cells and in vitro by cyclic AMP-dependent protein kinase and p34cdc2. J Biol Chem. 1993, 268 (27): 20076-20084.PubMed
72.
Leighton IA, Curmi P, Campbell DG, Cohen P, Sobel A: The phosphorylation of stathmin by MAP kinase. Mol Cell Biochem. 1993, 127–128: 151-156. 10.1007/BF01076766. 10.1007/BF01076766PubMed
73.
Honnappa S, Jahnke W, Seelig J, Steinmetz MO: Control of intrinsically disordered stathmin by multisite phosphorylation. J Biol Chem. 2006, 281 (23): 16078-16083. 10.1074/jbc.M513524200PubMed
74.
Collisson EA, Kleer C, Wu M, De A, Gambhir SS, Merajver SD, Kolodney MS: Atorvastatin prevents RhoC isoprenylation, invasion, and metastasis in human melanoma cells. Mol Cancer Ther. 2003, 2 (10): 941-948.PubMedCentralPubMed
75.
Liu HW, Halayko AJ, Fernandes DJ, Harmon GS, McCauley JA, Kocieniewski P, McConville J, Fu Y, Forsythe SM, Kogut P, Bellam S, Dowell M, Churchill J, Lesso H, Kassiri K, Mitchell RW, Hershenson MB, Camoretti-Mercado B, Solway J: The RhoA/Rho kinase pathway regulates nuclear localization of serum response factor. Am J Respir Cell Mol Biol. 2003, 29 (1): 39-47. 10.1165/rcmb.2002-0206OCPubMed
76.
Chen X, Knauf JA, Gonsky R, Wang M, Lai EH, Chissoe S, Fagin JA, Korenberg JR: From amplification to gene in thyroid cancer: a high-resolution mapped bacterial-artificial-chromosome resource for cancer chromosome aberrations guides gene discovery after comparative genome hybridization. Am J Hum Genet. 1998, 63 (2): 625-637. 10.1086/301973PubMedCentralPubMed
77.
Knauf JA, Elisei R, Mochly-Rosen D, Liron T, Chen XN, Gonsky R, Korenberg JR, Fagin JA: Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. J Biol Chem. 1999, 274 (33): 23414-23425. 10.1074/jbc.274.33.23414PubMed
78.
Martinez-Gimeno C, Diaz-Meco MT, Dominguez I, Moscat J: Alterations in levels of different protein kinase C isotypes and their influence on behavior of squamous cell carcinoma of the oral cavity: epsilon PKC, a novel prognostic factor for relapse and survival. Head Neck. 1995, 17 (6): 516-525. 10.1002/hed.2880170609PubMed
79.
Baxter G, Oto E, Daniel-Issakani S, Strulovici B: Constitutive presence of a catalytic fragment of protein kinase C epsilon in a small cell lung carcinoma cell line. J Biol Chem. 1992, 267 (3): 1910-1917.PubMed
80.
Bae KM, Wang H, Jiang G, Chen MG, Lu L, Xiao L: Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res. 2007, 67 (13): 6053-6063. 10.1158/0008-5472.CAN-06-4037PubMed
81.
Wu D, Foreman TL, Gregory CW, McJilton MA, Wescott GG, Ford OH, Alvey RF, Mohler JL, Terrian DM: Protein kinase cepsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res. 2002, 62 (8): 2423-2429.PubMed
82.
Cornford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, Foster CS: Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol. 1999, 154 (1): 137-144.PubMedCentralPubMed
83.
Brenner W, Benzing F, Gudejko-Thiel J, Fischer R, Farber G, Hengstler JG, Seliger B, Thuroff JW: Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells. Int J Oncol. 2004, 25 (4): 1157-1163.PubMed
84.
Varga A, Czifra G, Tallai B, Nemeth T, Kovacs I, Kovacs L, Biro T: Tumor grade-dependent alterations in the protein kinase C isoform pattern in urinary bladder carcinomas. Eur Urol. 2004, 46 (4): 462-465.PubMed
85.
Wheeler DL, Martin KE, Ness KJ, Li Y, Dreckschmidt NE, Wartman M, Ananthaswamy HN, Mitchell DL, Verma AK: Protein kinase C epsilon is an endogenous photosensitizer that enhances ultraviolet radiation-induced cutaneous damage and development of squamous cell carcinomas. Cancer Res. 2004, 64 (21): 7756-7765. 10.1158/0008-5472.CAN-04-1881PubMed
86.
Xiao H, Goldthwait DA, Mapstone T: The identification of four protein kinase C isoforms in human glioblastoma cell lines: PKC alpha, gamma, epsilon, and zeta. J Neurosurg. 1994, 81 (5): 734-740.PubMed
87.
Sharif TR, Sharif M: Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol. 1999, 15 (2): 237-243.PubMed
88.
Wheeler DL, Reddig PJ, Ness KJ, Leith CP, Oberley TD, Verma AK: Overexpression of protein kinase C-{epsilon} in the mouse epidermis leads to a spontaneous myeloproliferative-like disease. Am J Pathol. 2005, 166 (1): 117-126.PubMedCentralPubMed
Metadata
Title
Protein kinase Cε: an oncogene and emerging tumor biomarker
Authors
Michael A Gorin
Quintin Pan
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2009
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-8-9

Other articles of this Issue 1/2009

Molecular Cancer 1/2009 Go to the issue

Research

PRIMA-1MET induces nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 protein

Research

Identification of iGb3 and iGb4 in melanoma B16F10-Nex2 cells and the iNKT cell-mediated antitumor effect of dendritic cells primed with iGb3

Research

iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells

Research

Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors

Research

Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness

Research

Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits